Holen Sie sich die Stockscreener-App
20.34
0.39%
-0.08
Handel nachbörslich:
20.34
Schlusskurs vom Vortag:
$20.42
Offen:
$20.25
24-Stunden-Volumen:
353.25K
Relative Volume:
0.83
Marktkapitalisierung:
$520.86M
Einnahmen:
$219.79M
Nettoeinkommen (Verlust:
$-57.47M
KGV:
-9.4605
EPS:
-2.15
Netto-Cashflow:
$-19.25M
1W Leistung:
+6.16%
1M Leistung:
+27.36%
6M Leistung:
-23.68%
1J Leistung:
-4.01%
1-Tages-Spanne:
$20.01
$20.58
1-Wochen-Bereich:
$18.81
$20.63
52-Wochen-Spanne:
$15.45
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Vergleichen Sie CSTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
20.34 | 520.86M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
421.47 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.10 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.65 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.45 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences partners with SciBase for diagnostic tests - MSN
Castle Biosciences Inc (CSTL) Stock Price Down 4.54% on Jun 17 - GuruFocus
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com
Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha
Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - MarketScreener
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - Yahoo Finance
Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus
Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus
Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com
SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times
Castle Biosciences Enters Collaboration and License - GlobeNewswire
New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Barchart.com
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | CSTL Stock News - GuruFocus
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - The Manila Times
Castle Biosciences’ Chief Executive Officer Derek Maetzold - GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... - Bluefield Daily Telegraph
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Insider Monkey
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com Australia
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Castle Biosciences Inc-Aktie (CSTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 21 '25 |
Sale |
21.52 |
4,408 |
94,851 |
4,275 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 21 '25 |
Sale |
21.52 |
1,236 |
26,596 |
74,627 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 09 '25 |
Sale |
20.22 |
3,647 |
73,739 |
4,440 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 09 '25 |
Sale |
20.22 |
1,023 |
20,684 |
75,863 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 08 '25 |
Sale |
20.03 |
761 |
15,243 |
4,577 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Apr 08 '25 |
Sale |
20.03 |
213 |
4,266 |
76,886 |
0.17%
2.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):